1,4,6-triamino-2(1H)-pyrimidinethione | 4765-63-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1,4,6-triamino-2(1H)-pyrimidinethione
• 英文别名: 1,4,6-Triamino-2(1H)pyrimidine-thione；1,4,6-Triaminopyrimidine-2(1H)-thione；1,4,6-triaminopyrimidin-2-thione；1,4,6-triamino-1H-pyrimidine-2-thione；1,4,6-triamino-2(1H)-pyrimidine-thione；1,4,6-Triamino-2-thioxo-1,2-dihydro-pyrimidin；1,4,6-Triamino-1,2-dihydropyrimidine-2-thione；1,4,6-triaminopyrimidine-2-thione
• CAS: 4765-63-3
• 化学式: C₄H₇N₅S
• mdl: MFCD00457727
• 分子量: 157.199
• InChiKey: WTWHUODWOZTEOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,4,6-triamino-2(1H)-pyrimidinethione 在 甲酸 作用下， 以 水 为溶剂， 生成 7-amino-3H-[1,2,4]triazolo[1,5-c]pyrimidine-5-thione
  参考文献：
  名称：

  Cephalosporin derivatives

  摘要：

  本发明涉及新型头孢菌素衍生物、其制备方法、以新型头孢菌素衍生物作为活性成分的预防和/或治疗传染病的组合物，以及头孢菌素衍生物合成中的中间体化合物和其制备方法。本发明的新型头孢菌素衍生物包含紧缩杂环基团，特别是三唑嘧啶环或噻唑嘧啶环作为头孢菌素骨架的3位取代基，并且在头孢菌素骨架的7位取代基是羟肟基、烷氧基肟基或酰氧基肟基。本发明中含有上述取代基的化合物对革兰氏阴性菌和包括甲氧西林耐药金黄色葡萄球菌在内的革兰氏阳性菌具有强大的抗菌活性。这些化合物对于治疗传染病非常有用。

  公开号：

  US04888332A1
• 作为产物：
  描述：

  氨基硫脲 、 丙二腈 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 1,4,6-triamino-2(1H)-pyrimidinethione
  参考文献：
  名称：

  新型3-[（氨基嘧啶基）硫代]甲基头孢菌素的合成及抑菌活性。

  摘要：

  合成了一系列具有3-[（氨基嘧啶基）硫基]甲基取代基的新型头孢菌素化合物。它们对包括铜绿假单胞菌在内的各种细菌显示出很高的抗菌活性。还研究了与各种硫代嘧啶，硫代嘧啶，双环硫代三唑并嘧啶鎓和双环硫代咪唑并嘧啶鎓作为3'-取代基的结构活性关系；具有季铵化嘧啶鎓部分的头孢菌素比中性嘧啶头孢菌素具有更好的抗菌活性，并且使嘧啶鎓部分上的正电荷稳定对于更好的活性至关重要。根据半经验的PM3计算，嘧啶鎓环上的氨基和烷硫基取代基在电荷稳定和离域中起主要作用。

  DOI：

  10.1021/jm00048a018

文献信息

• Cephalosporin compounds
  申请人：Lucky, Ltd.

  公开号：US05202315A1

  公开（公告）日：1993-04-13

  The present invention relates to new cephalosporin compounds of the formula(I), pharmaceutically acceptable non-toxic salts thereof, and physiologically hydrolyzable esters and solvates thereof, which have potent and broad antibacterial activities ##STR1## wherein R.sup.1 is a C.sub.1.about.4 alkyl, C.sub.3.about.4 alkenyl, C.sub.3.about.4 alkynyl group, or --C(R.sup.a)(R.sup.b)CO.sub.2 H.sub.1 wherein R.sup.a and R.sup.b are the same or different, and each is a hydrogen atom or a C.sub.1.about.4 alkyl group, or R.sup.a and R.sup.b form a C.sub.3.about.7 cycloalkyl group with the carbon atom to which they are linked; R.sup.2 is a C.sub.1.about.4 alkyl, C.sub.3.about.4 alkenyl or C.sub.3.about.4 cycloalkyl group, a substituted or unsubstituted amino group, or a substituted or unsubstituted phenyl group; R.sup.3 is hydrogen or a C.sub.1.about.4 alkyl group; and Q is N or CH. The invention further relates to a process for preparing said compounds, and to pharamaceutical compositions containing said compounds.

  本发明涉及新的头孢菌素化合物的公式(I)，其药学上可接受的非毒性盐，以及具有强大和广谱抗菌活性的生理水解酯和溶剂化合物。其中R.sup.1是C.sub.1到4烷基，C.sub.3到4烯基，C.sub.3到4炔基，或--C(R.sup.a)(R.sup.b)CO.sub.2 H.sub.1，其中R.sup.a和R.sup.b相同或不同，且每个都是氢原子或C.sub.1到4烷基，或R.sup.a和R.sup.b形成与它们连接的碳原子的C.sub.3到7环烷基；R.sup.2是C.sub.1到4烷基，C.sub.3到4烯基或C.sub.3到4环烷基，一个取代或未取代的氨基团，或一个取代或未取代的苯基；R.sup.3是氢或C.sub.1到4烷基；Q是N或CH。该发明还涉及制备所述化合物的方法，以及含有所述化合物的药物组合物。
• Cephalosporin compounds and processes for the preparation thereof
  申请人：LUCKY LTD.

  公开号：EP0582261A1

  公开（公告）日：1994-02-09

  The present invention relates to a cephalosporin compound including the pharmaceutically acceptable non-toxic salts, physiologically hydrolyzable esters, hydrates and solvates thereof of the formula(I) and its isomers: wherein: R¹ isa C₁₋₄ alkyl, C₃₋₄ alkenyl, C₃₋₄ alkynyl or -C(Ra)(Rb)-COOH wherein Ra and Rb are, independently of each other, a hydrogen or a C₁₋₄ alkyl group, respectively, or jointly form a C₃₋₇ cycloalkyl group together with the carbon atoms to which they are attached; R² isa hydrogen or an amino which may be substituted or unsubstituted, alkoxy or heterocyclic group which is linked with a nitrogen atom; R³ isa hydrogen or a C₁₋₄ alkyl, amino, aminomethyl, hydroxy, hydroxymethyl, carboxy or carboxymethyl group; R⁴ isa hydrogen or a C₁₋₄ alkyl, amino, hydroxy, hydroxyalkl, acetamide, carboxyalkyl or sulfonylethyl group; R⁵ isa hydrogen or a C₁₋₄ alkyl, amino, carboxy, carboxyalkyl or hydroxy group; and Q and T areindependently CH or N, provided that R² is an amino group when T is N.

  本发明涉及一种头孢菌素化合物，包括其药学上可接受的非毒性盐、生理水解酯、水合物和溶剂化合物，其分子式为(I)及其异构体：其中：R¹为C₁₋₄烷基、C₃₋₄烯基、C₃₋₄炔基或-C(Ra)(Rb)-COOH，其中Ra和Rb分别为氢或C₁₋₄烷基，或者共同形成与它们连接的碳原子一起的C₃₋₇环烷基；R²为氢或与氮原子连接的可取代或不可取代的氨基、烷氧基或杂环基团；R³为氢或C₁₋₄烷基、氨基、氨甲基、羟基、羟甲基、羧基或羧甲基基团；R⁴为氢或C₁₋₄烷基、氨基、羟基、羟基烷基、乙酰胺基、羧基烷基或磺酰乙基基团；R⁵为氢或C₁₋₄烷基、氨基、羧基、羧基烷基或羟基基团；Q和T独立地为CH或N，条件是当T为N时，R²为氨基团。
• Intermediates cephalosporin derivatives
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：US05064953A1

  公开（公告）日：1991-11-12

  The present invention relates to novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in the synthesis of cephalosporin derivatives and processes for producing thereof. The novel cephalosporin derivatives according to the present invention contain condensed heterocyclic groups, particularly a triazolopyrimidine ring or a thiadiazolopyrimidine ring as substituents at the 3-position of the cephem skeleton, and a hydroxyimino, an alkyloxyimino or an acyloxyimino moiety as substituents at the 7-position of the cephem skeleton. The compounds of the present invention containing the aforementioned substituents have a strong antibacterial activity against gram-negative bacteria and also against gram-positive bacteria including methicillin-resistant Staphylococcus aureus. These compounds are extremely useful for the treatment of infectious diseases.

  本发明涉及新型头孢菌素衍生物，其制备方法，包含新型头孢菌素衍生物作为活性成分的预防和/或治疗传染病的组合物，以及头孢菌素衍生物合成中的中间体化合物和其制备方法。本发明中的新型头孢菌素衍生物含有紧凑的杂环基团，特别是三唑嘧啶环或噻唑嘧啶环作为头孢菌素骨架的3位取代基，并且羟肟基，烷氧肟基或酰氧肟基作为头孢菌素骨架的7位取代基。本发明中含有上述取代基的化合物对革兰氏阴性菌和包括甲氧西林耐药金黄色葡萄球菌在内的革兰氏阳性菌具有强烈的抗菌活性。这些化合物对于治疗传染病非常有用。
• Cephalosporin intermediates
  申请人：Lucky, Ltd.

  公开号：US05142041A1

  公开（公告）日：1992-08-25

  The present invention provides certain novel cephalosporin derivatives represented by following formula(I), which are especially useful as intermediates for the preparation of cephalosporin compounds possessed with potent and broad antibacterial activities. ##STR1## wherein: R.sup.1 is a C.sub.1-4 alkyl, C.sub.3-4 alkenyl, C.sub.3-4 cycloalkyl, amino optionally substituted with a C.sub.1-4 alkyl radical, or phenyl group optionally substituted on its 2-, 4-and/or 6-position with a halogen, C.sub.1-4 alkyl, C.sub.1-3 alkoxy or hydroxy radical; R.sup.2 is hydrogen or a C.sub.1-4 alkyl group; and n is either 0 or 1. The invention also relates to processes for preparing these intermediates and their pharmacologically active cephalosporin antibiotics.

  本发明提供了一些新型头孢菌素衍生物，其表示为以下公式(I)，特别适用于制备具有强大和广谱抗菌活性的头孢菌素化合物的中间体。##STR1## 其中：R.sup.1是C.sub.1-4烷基，C.sub.3-4烯基，C.sub.3-4环烷基，氨基，可选地被C.sub.1-4烷基基团取代，或苯基，其可选地在其2-、4-和/或6-位上被卤素，C.sub.1-4烷基，C.sub.1-3烷氧基或羟基基团取代；R.sup.2是氢或C.sub.1-4烷基基团；n为0或1。本发明还涉及制备这些中间体及其药理活性头孢菌素抗生素的方法。
• Synthesis of certain derivatives of a new heterocyclic system-pyrimido[3,4-b]-l,2,4-triazine-and their antitumorigenic activity
  作者：T. G. Koksharova、L. N. Dianova、N. V. Volkova、O. S. Anisimova、G. M. Anoshina、G. V. Sverchnikova

  DOI：10.1007/bf00763521

  日期：1988.7

  The reaction was carried out in 30% alcohol and 5% acetic acid, and the ratio of the pyrimidine-thione/pyruvic acid reagents was 1:3. In aqueous alcohol, the reaction took 12 h, while in acetic acid, it was complete in 2 h. The TLC, IR, PMR and mass spectroscopy data showed that the product of this reaction (III) was isolated in individual state and had the same structure, irrespective of the solvent

  反应在30%乙醇和5%乙酸中进行，嘧啶-硫酮/丙酮酸试剂的比例为1:3。在乙醇水溶液中，反应需要 12 小时，而在乙酸中，反应在 2 小时内完成。TLC、IR、PMR 和质谱数据表明，无论使用何种溶剂，该反应 (III) 的产物均以单独的状态分离并具有相同的结构。我们没有观察到具有异构结构（III和IIIa）的化合物混合物的形成